The evaluating prescription opioid changes in veterans (EPOCH) study: Design, survey response, and baseline characteristics

Erin E. Krebs, Barbara Clothier, Sean Nugent, Agnes C. Jensen, Brian C. Martinson, Elizabeth S. Goldsmith, Melvin T. Donaldson, Joseph W. Frank, Indulis Rutks, Siamak Noorbaloochi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

In the United States (US), long-term opioid therapy has been commonly prescribed for chronic pain. Since recognition of the opioid overdose epidemic, clinical practice guidelines have recommended tapering long-term opioids to reduced doses or discontinuation. The Effects of Prescription Opioid Changes for veterans (EPOCH) study is a national population-based prospective observational study of US Veterans Health Administration primary care patients designed to assess effects of evolving opioid prescribing practice on patients treated with long-term opioids for chronic pain. A stratified random sampling design was used to identify a survey sample from the target population of patients treated with opioid analgesics for ≥ 6 months. Demographic, diagnostic, visit, and pharmacy dispensing data were extracted from existing datasets. A 2016 mixed-mode mail and telephone survey collected patient-reported data, including the main patient-reported outcomes of pain-related function (Brief Pain Inventory interference; BPI-I scores 0–10, higher scores = worse) and health-related quality of life. Data on survey participants and non-participants were analyzed to assess potential nonresponse bias. Weights were used to account for design. Linear regression models were used to assess cross-sectional associations of opioid treatment with patient-reported measures. Of 14,160 patients contacted, 9253 (65.4%) completed the survey. Participants were older than non-participants (63.9 ± 10.6 vs. 59.6 ± 13.0 years). The mean number of bothersome pain locations was 6.8 (SE 0.04). Effectiveness of pain treatment and quality of pain care were rated fair or poor by 56.1% and 45.3%, respectively. The opioid daily dosage range was 1.6 to 1038.2 mg, with mean = 50.6 mg (SE 1.1) and median = 30.9 mg (IQR 40.7). Among the 73.2% of patients who did not receive long-acting opioids, the mean daily dosage was 30.4 mg (SE 0.6) and mean BPI-I was 6.4 (SE 00.4). Among patients who received long-acting opioids, the mean daily dosage was 106.2 mg (SE 2.8) and mean BPI-I was 6.8 (SE 0.07). Higher daily dosage was associated with worse pain-related function and quality of life among patients without long-acting opioids, but not among patients with long-acting opioids. Future analyses will use follow-up data to examine effects of opioid dose reduction and discontinuation on patient outcomes.

Original languageEnglish (US)
Article numbere0230751
JournalPloS one
Volume15
Issue number4
DOIs
StatePublished - Apr 2020

Bibliographical note

Funding Information:
The study was supported by the United States Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (IIR 14-295 to EEK and CDA 15-059 to JWF) and National Institutes of Health (F30AT009162 to MTD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'The evaluating prescription opioid changes in veterans (EPOCH) study: Design, survey response, and baseline characteristics'. Together they form a unique fingerprint.

Cite this